Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Fox

Showing results (61-70 of 141) with videos related to

Pageof 15
Sort By:
Plos One|March 11, 2021
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse modelSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
Journal of Substance Use and Addiction Treatment|September 7, 2024
Peer-Assisted Telemedicine for Hepatitis C (PATHS): Process evaluation results from a State Opioid Response-funded programHunter Spencer, Gillian Leichtling, Jane Babiarz, et al.
AAPS Pharmscitech|December 22, 2016
Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical CartridgeLucien Barnes V, Dawn M Fedor, Simon Williams, et al.
Vaccine|November 7, 2015
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacyMark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Pharmaceuticals (Basel, Switzerland)|August 1, 2020
Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic ResponseTony Phan, Christian Devine, Erik D Laursen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2016
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist AdjuvantsAnthony L Desbien, Natasha Dubois Cauwelaert, Steven J Reed, et al.
Frontiers in Microbiology|September 12, 2022
Therapeutic efficacy against <i>Mycobacterium tuberculosis</i> using ID93 and liposomal adjuvant formulationsSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
European Journal of Immunology|November 5, 2014
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γAnthony L Desbien, Steven J Reed, Hilton R Bailor, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|September 30, 2025
Development of Exclusive and Efficient Intranasal or Pulmonary Dosing Methods for a Dry Powder Tuberculosis Vaccine for Use in Nonhuman PrimatesJohn Z Chen, Scott Tavernini, Maximilian Aisenstat, et al.
Colloids and Surfaces. B, Biointerfaces|September 15, 2009
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsRyan C Anderson, Christopher B Fox, Timothy S Dutill, et al.
Pageof 15

Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Plos One|March 11, 2021
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse modelSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
Journal of Substance Use and Addiction Treatment|September 7, 2024
Peer-Assisted Telemedicine for Hepatitis C (PATHS): Process evaluation results from a State Opioid Response-funded programHunter Spencer, Gillian Leichtling, Jane Babiarz, et al.
AAPS Pharmscitech|December 22, 2016
Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical CartridgeLucien Barnes V, Dawn M Fedor, Simon Williams, et al.
Vaccine|November 7, 2015
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacyMark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Pharmaceuticals (Basel, Switzerland)|August 1, 2020
Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic ResponseTony Phan, Christian Devine, Erik D Laursen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2016
IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist AdjuvantsAnthony L Desbien, Natasha Dubois Cauwelaert, Steven J Reed, et al.
Frontiers in Microbiology|September 12, 2022
Therapeutic efficacy against <i>Mycobacterium tuberculosis</i> using ID93 and liposomal adjuvant formulationsSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
European Journal of Immunology|November 5, 2014
Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γAnthony L Desbien, Steven J Reed, Hilton R Bailor, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|September 30, 2025
Development of Exclusive and Efficient Intranasal or Pulmonary Dosing Methods for a Dry Powder Tuberculosis Vaccine for Use in Nonhuman PrimatesJohn Z Chen, Scott Tavernini, Maximilian Aisenstat, et al.
Colloids and Surfaces. B, Biointerfaces|September 15, 2009
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsRyan C Anderson, Christopher B Fox, Timothy S Dutill, et al.
Pageof 15